Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Share-based Compensation: 2015-2024

Historic Share-based Compensation for Wave Life Sciences (WVE) over the last 10 years, with Dec 2024 value amounting to $13.1 million.

  • Wave Life Sciences' Share-based Compensation rose 83.29% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 70.34%. This contributed to the annual value of $13.1 million for FY2024, which is 34.16% up from last year.
  • According to the latest figures from FY2024, Wave Life Sciences' Share-based Compensation is $13.1 million, which was up 34.16% from $9.8 million recorded in FY2023.
  • In the past 5 years, Wave Life Sciences' Share-based Compensation registered a high of $17.2 million during FY2022, and its lowest value of $9.8 million during FY2023.
  • Over the past 3 years, Wave Life Sciences' median Share-based Compensation value was $13.1 million (recorded in 2024), while the average stood at $13.4 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 43.03% in 2023, then surged by 34.16% in 2024.
  • Yearly analysis of 5 years shows Wave Life Sciences' Share-based Compensation stood at $14.3 million in 2020, then increased by 14.77% to $16.4 million in 2021, then grew by 4.80% to $17.2 million in 2022, then plummeted by 43.03% to $9.8 million in 2023, then spiked by 34.16% to $13.1 million in 2024.